Resistance to lorlatinib in ROS1 fusion | 合法藥品大搜索

由JJLin著作·2020·被引用6次—Background:Lorlatinibisapotent,brain-penetrantROS1/ALKtyrosinekinaseinhibitor(TKI),whichhasdemonstratedefficacyinadvancedROS1 ...

9611

Background: Lorlatinib is a potent, brain-penetrant ROS1/ALK tyrosine kinase inhibitor (TKI), which has demonstrated efficacy in advanced ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC), including in patients (pts) previously treated with crizotinib. Despite initial benefit, however, most pts experience disease progression on lorlatinib. Mechanisms of resistance to lorlatinib in ROS1+ NSCLC are poorly understood. Methods: We analyzed repeat tumor biopsies derived from advanced ROS1+ lung cancer pts progressing on lorlatinib. Next-generation sequencing (NGS, n = 17) or whole exome sequencing (n = 1) was performed to detect mutations, indels, and copy number alterations. Results: Sixteen pts underwent a total of 18 repeat tumor biopsies after progression on lorlatinib. Fourteen had received prior crizotinib; two received prior crizotinib and entrectinib. Median duration of the...

Lorlatinib in advanced ROS1-positive non | 合法藥品大搜索

由 AT Shaw 著作 · 2019 · 被引用 106 次 — Lorlatinib is a potent, brain-penetrant, third-generation tyrosine kinase inhibitor (TKI) that targets ALK and ROS1 with preclinical activity against ... Read More

Lorlatinib in ROS1 | 合法藥品大搜索

由 B Solomon 著作 — Lorlatinib is a novel macrocyclic inhibitor of both the ALK and ROS1 kinases. The overall and intracranial activity of lorlatinib in patients with ALK- ... Read More

Lorlatinib in advanced ROS1-positive non | 合法藥品大搜索

由 AT Shaw 著作 · 2019 · 被引用 106 次 — Background: Lorlatinib is a potent, brain-penetrant, third-generation tyrosine kinase inhibitor (TKI) that targets ALK and ROS1 with preclinical activity against most ... Read More

Later | 合法藥品大搜索

由 MJ Hochmair 著作 · 2020 · 被引用 2 次 — In clinical practice, patients with anaplastic lymphoma kinase (ALK)-rearrangement-positive non-small-cell lung cancer commonly receive ... Read More

Lorlatinib in ROS1 | 合法藥品大搜索

由 D Killock 著作 · 2020 · 被引用 3 次 — The tyrosine-kinase inhibitors (TKIs) crizotinib and entrectinib have been approved by the FDA for the treatment of ROS1-positive ... Read More

Resistance to lorlatinib in ROS1 fusion | 合法藥品大搜索

由 JJ Lin 著作 · 2020 · 被引用 6 次 — Background: Lorlatinib is a potent, brain-penetrant ROS1/ALK tyrosine kinase inhibitor (TKI), which has demonstrated efficacy in advanced ROS1 ... Read More

Lorlatinib in ALK- and ROS1 | 合法藥品大搜索

Lorlatinib in ALK- and ROS1-positive NSCLC: the future has a start. Francesco Facchinetti1, Luc Friboulet2. 1Medical Oncology Unit, University Hospital of Parma , ... Read More

Lorlatinib in Advanced ROS1 | 合法藥品大搜索

2019年11月25日 — “Lorlatinib showed clinical activity in patients with advanced ROS1-positive NSCLC, including those with central nervous system metastases and ... Read More

1368P Lorlatinib in pretreated ALKROS1 | 合法藥品大搜索

由 N Frost 著作 · 2020 — The third-generation ALK- and ROS1 inhibitor lorlatinib has demonstrated clinical efficacy in several trials. We here report on the results of the German early ... Read More

相關資訊整理